Report Summary
Eternity Insights has published a new study on Global Choroidal Neovascularization Drug Market focusing on key segments as by Type (AVMOC-001,BB-3,BBT-007,DG-3,Entolimod,EWA-001,Others), by Application (Clinic,Hospital,Others), and by region. This deep dive re-search report highlights the market and competitive intelligence across the key segments of the mar-ket. The report also considers the impact of COVID-19 on the global Choroidal Neovascularization Drug Market.
The report considers 2018-2020 as historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the market drivers, challenges, and trends to accurately map the market scenario and competition. Moreover, key insights related to market having direct impact on the market will also be covered.
Choroidal Neovascularization Drug Market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
Global Choroidal Neovascularization Drug Market Size, 2018-2028 (USD Million)
To learn more about this report
Global Choroidal Neovascularization Drug Market Segmentation:
Choroidal Neovascularization Drug Market, By Type
- AVMOC-001
- BB-3
- BBT-007
- DG-3
- Entolimod
- EWA-001
- Others
Choroidal Neovascularization Drug Market, By Application
To learn more about this report
Geographically, the market is categorized in to five regions as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region dominates the global Choroidal Neovascularization Drug market in terms of demand generation. The Choroidal Neovascularization Drug market in Asia Pacific region is expected to grow at significantly high growth rate. The regional market is further sub-segmented and analyzed at granular level across key countries. The report will include market size and forecast for Choroidal Neovascularization Drug market for below listed coun-tries across each region.
North America (U.S. and Canada), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific region); Latin America (Brazil, Mexico, and rest of the Latin America); Middle East and Africa (GCC, South Africa, and Rest of the Middle East and Africa).
Global Choroidal Neovascularization Drug Market Taxonomy:
To learn more about this report
Global Choroidal Neovascularization Drug Market Competitive Landscape
The global Choroidal Neovascularization Drug market analysis report covers detailed analysis of competitive scenario across globe. The report includes profiles of leading players covering below details
- Company Overview
- Financial Analysis
- Product Portfolio Analysis
- Strategic Overview
- SWOT Analysis
List of Companies Profiled in the report:
- Cellphire
- Inc.
- Chrysalis BioTherapeutics
- Inc.
- Cleveland BioLabs
- Inc.
- Cumberland Pharmaceuticals
- Inc.
- Diffusion Pharmaceuticals Inc.
- Eli Lilly and Company
- GNI Group Ltd.
- Humanetics Corporation
- INSYS Therapeutics
- Inc.
- Meabco A/S
- Neumedicines Inc.
- Onconova Therapeutics
- Inc.
- PharmaIN Corporation
- Pluristem Therapeutics Inc.
- ProCertus BioPharm Inc.
- RDD Pharma Ltd.
- RedHill Biopharma Ltd.
- RxBio
- Inc.
- Soligenix
- Inc.
- Other Players of Specific Interest can be added based on requirement
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
AVMOC-001,BB-3,BBT-007,DG-3,Entolimod,EWA-001,Others |
| By Application Outlook |
Clinic,Hospital,Others |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Cellphire, Inc.,Chrysalis BioTherapeutics, Inc.,Cleveland BioLabs, Inc.,Cumberland Pharmaceuticals, Inc.,Diffusion Pharmaceuticals Inc.,Eli Lilly and Company,GNI Group Ltd.,Humanetics Corporation,INSYS Therapeutics, Inc.,Meabco A/S,Neumedicines Inc.,Onconova Therapeutics, Inc.,PharmaIN Corporation,Pluristem Therapeutics Inc.,ProCertus BioPharm Inc.,RDD Pharma Ltd.,RedHill Biopharma Ltd.,RxBio, Inc.,Soligenix, Inc. |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Benefits to the stake holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
Table Of Contents
Table of Contents
1 Report Overview
1.1 Definition
1.2 Manufacturers and Regions Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.3 Type Overview
1.4 Application Overview
1.5 Industrial Chain
1.5.1 Choroidal Neovascularization Drug Overall Industrial Chain
1.5.2 Upstream
1.5.3 Downstream
1.5.4 Economic/Political Environment
2 Global Choroidal Neovascularization Drug Market Assesment by Types
2.1 Overall Market Performance
2.1.1 Product Type Market Performance (Volume)
2.1.2 Product Type Market Performance (Value)
2.2 China Choroidal Neovascularization Drug Market Performance
2.3 USA Choroidal Neovascularization Drug Market Performance
2.4 Europe Choroidal Neovascularization Drug Market Performance
2.5 Japan Choroidal Neovascularization Drug Market Performance
2.6 Korea Choroidal Neovascularization Drug Market Performance
2.7 India Choroidal Neovascularization Drug Market Performance
2.8 Southeast Asia Choroidal Neovascularization Drug Market Performance
2.9 South America Choroidal Neovascularization Drug Market Performance
3 Global Choroidal Neovascularization Drug Market Assesment by Application
3.1 Overall Market Performance (Volume)
3.2 China Choroidal Neovascularization Drug Market Performance (Volume)
3.3 USA Choroidal Neovascularization Drug Market Performance (Volume)
3.4 Europe Choroidal Neovascularization Drug Market Performance (Volume)
3.5 Japan Choroidal Neovascularization Drug Market Performance (Volume)
3.6 Korea Choroidal Neovascularization Drug Market Performance (Volume)
3.7 India Choroidal Neovascularization Drug Market Performance (Volume)
3.8 Southeast Asia Choroidal Neovascularization Drug Market Performance (Volume)
3.9 South America Choroidal Neovascularization Drug Market Performance (Volume)
4 Competitive Analysis
4.1 Cellphire, Inc.
4.1.1 Cellphire, Inc. Profiles
4.1.2 Cellphire, Inc. Product Information
4.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Business Performance
4.1.5 SWOT Analysis
4.2 Chrysalis BioTherapeutics, Inc.
4.2.1 Chrysalis BioTherapeutics, Inc. Profiles
4.2.2 Chrysalis BioTherapeutics, Inc. Product Information
4.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Business Performance
4.2.5 SWOT Analysis
4.3 Cleveland BioLabs, Inc.
4.3.1 Cleveland BioLabs, Inc. Profiles
4.3.2 Cleveland BioLabs, Inc. Product Information
4.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Business Performance
4.3.5 SWOT Analysis
4.4 Cumberland Pharmaceuticals, Inc.
4.4.1 Cumberland Pharmaceuticals, Inc. Profiles
4.4.2 Cumberland Pharmaceuticals, Inc. Product Information
4.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Business Performance
4.4.5 SWOT Analysis
4.5 Diffusion Pharmaceuticals Inc.
4.5.1 Diffusion Pharmaceuticals Inc. Profiles
4.5.2 Diffusion Pharmaceuticals Inc. Product Information
4.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Business Performance
4.5.5 SWOT Analysis
4.6 Eli Lilly and Company
4.6.1 Eli Lilly and Company Profiles
4.6.2 Eli Lilly and Company Product Information
4.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Business Performance
4.6.5 SWOT Analysis
4.7 GNI Group Ltd.
4.7.1 GNI Group Ltd. Profiles
4.7.2 GNI Group Ltd. Product Information
4.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Business Performance
4.7.5 SWOT Analysis
4.8 Humanetics Corporation
4.8.1 Humanetics Corporation Profiles
4.8.2 Humanetics Corporation Product Information
4.8.3 Humanetics Corporation Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.8.4 Humanetics Corporation Choroidal Neovascularization Drug Business Performance
4.8.5 SWOT Analysis
4.9 INSYS Therapeutics, Inc.
4.9.1 INSYS Therapeutics, Inc. Profiles
4.9.2 INSYS Therapeutics, Inc. Product Information
4.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Business Performance
4.9.5 SWOT Analysis
4.10 Meabco A/S
4.10.1 Meabco A/S Profiles
4.10.2 Meabco A/S Product Information
4.10.3 Meabco A/S Choroidal Neovascularization Drug Production, Revenue, Price and Gross Margin
4.10.4 Meabco A/S Choroidal Neovascularization Drug Business Performance
4.10.5 SWOT Analysis
4.11 Neumedicines Inc.
4.12 Onconova Therapeutics, Inc.
4.13 PharmaIN Corporation
4.14 Pluristem Therapeutics Inc.
4.15 ProCertus BioPharm Inc.
4.16 RDD Pharma Ltd.
4.17 RedHill Biopharma Ltd.
4.18 RxBio, Inc.
4.19 Soligenix, Inc.
5 Competitive Landscape
5.1 Global Choroidal Neovascularization Drug Production (K Units) and Market Share by Manufacturers (2014-2020)
5.2 Global Choroidal Neovascularization Drug Revenue (M USD) and Market Share by Manufacturers (2014-2020)
5.3 Global Choroidal Neovascularization Drug Price (USD/Unit) of Manufacturers (2014-2020)
5.4 Global Choroidal Neovascularization Drug Gross Margin of Manufacturers (2014-2020)
5.5 Market Concentration
6 Global Choroidal Neovascularization Drug Market Assessment by Regions
6.1 Global Choroidal Neovascularization Drug Production (K Units) and Market Share by Regions (2014-2020)
6.2 Global Choroidal Neovascularization Drug Revenue (M USD) and Market Share by Regions (2014-2020)
6.3 Global Choroidal Neovascularization Drug Price (USD/Unit) by Regions (2014-2020)
6.4 Global Choroidal Neovascularization Drug Gross Margin by Regions (2014-2020)
7 Choroidal Neovascularization Drug Regional Analysis
7.1 China Choroidal Neovascularization Drug Production, Revenue and Growth Rate (2014-2020)
7.2 USA Choroidal Neovascularization Drug Production, Revenue and Growth Rate (2014-2020)
7.3 Europe Choroidal Neovascularization Drug Production, Revenue and Growth Rate (2014-2020)
7.4 Japan Choroidal Neovascularization Drug Production, Revenue and Growth Rate (2014-2020)
7.5 Korea Choroidal Neovascularization Drug Production, Revenue and Growth Rate (2014-2020)
7.6 India Choroidal Neovascularization Drug Production, Revenue and Growth Rate (2014-2020)
7.7 Southeast Asia Choroidal Neovascularization Drug Production, Revenue and Growth Rate (2014-2020)
7.8 South America Choroidal Neovascularization Drug Production, Revenue and Growth Rate (2014-2020)
8 Global Choroidal Neovascularization Drug Consumption Assessment
8.1 Global Choroidal Neovascularization Drug Consumption and Market Share by Regions (2014-2020)
8.2 Global Choroidal Neovascularization Drug Consumption Value and Market Share by Regions (2014-2020)
8.3 Global Choroidal Neovascularization Drug Average Price (USD/Unit) by Regions (2014-2020)
9 Global Choroidal Neovascularization Drug Sales Assessment by Regions
9.1 Global Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
9.2 China Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
9.3 USA Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
9.4 Europe Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
9.5 Japan Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
9.6 Korea Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
9.7 India Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
9.8 Southeast Asia Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
9.9 South America Choroidal Neovascularization Drug Sales and Sales Value (2014-2020)
10 Technology and Cost
10.1 Technology
10.2 Cost
11 Channel Analysis
11.1 Market Channel
11.2 Distributors
12 Market Forecast 2021-2026
12.1 Production and Revenue Forecast 2021-2026
12.1.1 Global Choroidal Neovascularization Drug Production and Revenue by Regions 2021-2026
12.1.2 China Choroidal Neovascularization Drug Production, Revenue and Growth Rate 2021-2026
12.1.3 USA Choroidal Neovascularization Drug Production, Revenue and Growth Rate 2021-2026
12.1.4 Europe Choroidal Neovascularization Drug Production, Revenue and Growth Rate 2021-2026
12.1.5 Japan Choroidal Neovascularization Drug Production, Revenue and Growth Rate 2021-2026
12.1.6 Korea Choroidal Neovascularization Drug Production, Revenue and Growth Rate 2021-2026
12.1.7 India Choroidal Neovascularization Drug Production, Revenue and Growth Rate 2021-2026
12.1.8 Southeast Asia Choroidal Neovascularization Drug Production, Revenue and Growth Rate 2021-2026
12.1.9 South America Choroidal Neovascularization Drug Production, Revenue and Growth Rate 2021-2026
12.2 Sales and Sales Value Forecast 2021-2026
12.2.1 Global Choroidal Neovascularization Drug Consumption and Consumption Calue by Regions 2021-2026
12.2.2 Global Choroidal Neovascularization Drug Sales and Sales Value Forecast 2021-2026
12.2.3 China Choroidal Neovascularization Drug Sales, Sales Value and Growth Rate 2021-2026
12.2.4 USA Choroidal Neovascularization Drug Sales and Sales Value Forecast 2021-2026
12.2.5 Europe Choroidal Neovascularization Drug Sales and Sales Value Forecast 2021-2026
12.2.6 Japan Choroidal Neovascularization Drug Sales and Sales Value Forecast 2021-2026
12.2.7 Korea Choroidal Neovascularization Drug Sales and Sales Value Forecast 2021-2026
12.2.8 India Choroidal Neovascularization Drug Sales and Sales Value Forecast 2021-2026
12.2.9 Southeast Asia Choroidal Neovascularization Drug Sales and Sales Value Forecast 2021-2026
12.2.10 South America Choroidal Neovascularization Drug Sales and Sales Value Forecast 2021-2026
12.3 Global Choroidal Neovascularization Drug Production and Revenue Forecast by Type 2021-2026
12.3.1 Overall Market Performance
12.3.2 AVMOC-001
12.3.3 BB-3
12.3.4 BBT-007
12.3.5 DG-3
12.3.6 Entolimod
12.3.7 EWA-001
12.3.8 Others
12.4 Global Choroidal Neovascularization Drug Sales Forecast by Application 2021-2026
12.4.1 Overall Market Performance
12.4.2 Clinic
12.4.3 Hospital
12.4.4 Others
12.5 Global Choroidal Neovascularization Drug Price and Gross Margin Forecast
13.5.1 Global Choroidal Neovascularization Drug Averages Price Development Trend Forecast 2021-2026
13.5.2 Global Choroidal Neovascularization Drug Gross Margin Development Trend Forecast 2021-2026
13 Conclusion
